More on NBIX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $136.95 |
|
|||
| Open | $137.86 | ||||
| 52 Wk High | $58.46 | ||||
| 52 Wk Low | $31.25 | ||||
| Day High | $138.20 | ||||
| Day Low | $135.55 | ||||
| P/E | N/A | ||||
| EPS | $-0.69 | ||||
| Volume | 1,127,483 | ||||
- Neurocrine presents real-world CAH patient journey data at nursing symposium
- Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
- Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: JPMORGAN CHASE & CO
- TD Cowen: 'Neurocrine Bio. (NBIX) Growth Story Appears Intact'
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
- Neurocrine Bio. (NBIX) PT Lowered to $150 at BMO Capital
- Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'
- Form 3 NEUROCRINE BIOSCIENCES For: Sep 28 Filed by: ROBERTS EIRY
- Guggenheim Assumes Neurocrine Bio. (NBIX) at Buy
- Neurocrine to present Vykat XR and PWS research at FPWR conference
Entities mentioned with NBIX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
